Edinburgh Research Explorer

Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial

Research output: Contribution to journalArticle

  • William MacNee
  • Richard J Allan
  • Ieuan Jones
  • Maria Cristina De Salvo
  • Lisa F Tan

Related Edinburgh Organisations

Original languageEnglish
Pages (from-to)738-45
Number of pages8
JournalThorax
Volume68
Issue number8
DOIs
Publication statusPublished - Aug 2013

Abstract

Chronic obstructive pulmonary disease (COPD) is a common lung disease leading to progressive decline in lung function. Inhibition of release of inflammatory mediators by p38 inhibitors may be a useful treatment for chronic inflammation of the airways thought to underlie the pathogenesis of the disease.

    Research areas

  • Administration, Oral, Adult, Aged, Aged, 80 and over, Benzamides, C-Reactive Protein, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Forced Expiratory Volume, Humans, Male, Middle Aged, Pulmonary Disease, Chronic Obstructive, Pyridones, Retrospective Studies, Severity of Illness Index, Spirometry, Treatment Outcome, p38 Mitogen-Activated Protein Kinases

ID: 15019275